Bloomberg
Loading video player...

Novo Raises Forecast as Wegovy Pill Fuels Sales

Share

Novo Nordisk said this year's declines won't be as bad as initially expected thanks to the new Wegovy pill, which helped fuel sales in the first quarter. For the year, the worst drop for both profit and sales will be 12%, compared with 13% earlier. Bloomberg's Sanne Wass reports from Copenhagen.

Connect with us

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.